Your browser doesn't support javascript.
loading
MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer.
Gawrzak, Sylwia; Rinaldi, Lorenzo; Gregorio, Sara; Arenas, Enrique J; Salvador, Fernando; Urosevic, Jelena; Figueras-Puig, Cristina; Rojo, Federico; Del Barco Barrantes, Ivan; Cejalvo, Juan Miguel; Palafox, Marta; Guiu, Marc; Berenguer-Llergo, Antonio; Symeonidi, Aikaterini; Bellmunt, Anna; Kalafatovic, Daniela; Arnal-Estapé, Anna; Fernández, Esther; Müllauer, Barbara; Groeneveld, Rianne; Slobodnyuk, Konstantin; Stephan-Otto Attolini, Camille; Saura, Cristina; Arribas, Joaquín; Cortes, Javier; Rovira, Ana; Muñoz, Montse; Lluch, Ana; Serra, Violeta; Albanell, Joan; Prat, Aleix; Nebreda, Angel R; Benitah, Salvador Aznar; Gomis, Roger R.
Affiliation
  • Gawrzak S; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Rinaldi L; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Gregorio S; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Arenas EJ; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Salvador F; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Urosevic J; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Figueras-Puig C; CIBERONC, Madrid, Spain.
  • Rojo F; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Del Barco Barrantes I; CIBERONC, Madrid, Spain.
  • Cejalvo JM; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
  • Palafox M; Pathology Department, IIS-Fundación Jimenez Diaz, Madrid, Spain.
  • Guiu M; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Berenguer-Llergo A; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Symeonidi A; Translational Genomics and Targeted Therapeutics, Institut d'Investigacions Biomèdiques Pi i Sunyer-IDIBAPS, Barcelona, Spain.
  • Bellmunt A; Experimental Therapeutics, Vall d'Hebron Insitute of Oncology, Barcelona, Spain.
  • Kalafatovic D; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Arnal-Estapé A; CIBERONC, Madrid, Spain.
  • Fernández E; Biostatistics and Bioinformatics Unit, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Müllauer B; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Groeneveld R; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Slobodnyuk K; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Stephan-Otto Attolini C; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Saura C; Department of Pathology, Yale University School of Medicine, Yale, CT, USA.
  • Arribas J; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Cortes J; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Rovira A; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Muñoz M; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Lluch A; Biostatistics and Bioinformatics Unit, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Serra V; Department of Oncology, Vall d'Hebrón University Hospital, Barcelona, Spain.
  • Albanell J; Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Prat A; CIBERONC, Madrid, Spain.
  • Nebreda AR; Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Benitah SA; Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Gomis RR; ICREA, Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain.
Nat Cell Biol ; 20(2): 211-221, 2018 02.
Article de En | MEDLINE | ID: mdl-29358704

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du sein / Ribosomal Protein S6 Kinases, 90-kDa / Facteur de transcription GATA-3 / Facteur nucléaire hépatocytaire HNF-3 alpha Type d'étude: Prognostic_studies Limites: Adult / Aged / Animals / Female / Humans / Middle aged Langue: En Journal: Nat Cell Biol Année: 2018 Type de document: Article Pays d'affiliation: Espagne

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du sein / Ribosomal Protein S6 Kinases, 90-kDa / Facteur de transcription GATA-3 / Facteur nucléaire hépatocytaire HNF-3 alpha Type d'étude: Prognostic_studies Limites: Adult / Aged / Animals / Female / Humans / Middle aged Langue: En Journal: Nat Cell Biol Année: 2018 Type de document: Article Pays d'affiliation: Espagne